(3R,4S,5R,6R)-4-[(2R,3R,4S,5S,6R)-6-[[(2S,3R,4S,5R,6R)-3,5-Dihydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol

Term ID

CHEBI:150794

Synonyms

alpha-D-gluco-hexopyranosyl-(1->3)-alpha-D-gluco-hexopyranosyl-(1->6)-alpha-D-gluco-hexopyranosyl-(1->3)-D-gluco-hexopyranose
Glc(a1-3)Glc(a1-6)Glc(a1-3)Glc
WURCS=2.0/2,4,3/[a2122h-1x_1-5][a2122h-1a_1-5]/1-2-2-2/a3-b1_b6-c1_c3-d1

Definition

References

GlyGen:G43116LH
GlyTouCan:G43116LH

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from (3R,4S,5R,6R)-4-[(2R,3R,4S,5S,6R)-6-[[(2S,3R,4S,5R,6R)-3,5-Dihydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol

Phenotype where environments contain (3R,4S,5R,6R)-4-[(2R,3R,4S,5S,6R)-6-[[(2S,3R,4S,5R,6R)-3,5-Dihydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol

Phenotype modified by environments containing (3R,4S,5R,6R)-4-[(2R,3R,4S,5S,6R)-6-[[(2S,3R,4S,5R,6R)-3,5-Dihydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol

Phenotype affecting (3R,4S,5R,6R)-4-[(2R,3R,4S,5S,6R)-6-[[(2S,3R,4S,5R,6R)-3,5-Dihydroxy-6-(hydroxymethyl)-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol

Human Disease Model